Zynteglo Could Be Gene Therapy Test Case For Viability Of Outcomes-Based Contracts

Zynteglo Could Be Gene Therapy Test Case For Viability Of Outcomes-Based Contracts – UHC Exec

21 Jun 2022

Outcomes and disease progression could be clear cut, lending the rare disease treatment to innovative contracting. But the amount of money at stake is likely to complicate things.

Outcomes-Based Contracts May Be Harder With Future Gene Therapies • Source: Shutterstock

bluebird bio is actively pursuing outcomes-based contracts for its Zynteglo gene therapy for beta thalassemia in the US, if cleared for marketing, which could serve as an important precedent for the feasibility of outcomes-based contracts for such cutting edge therapies, according to UnitedHealthcare Pharmacy director of emerging therapeutics and outcomes-based contracting Erik Schindler.

Prospects for outcomes-based, risk-sharing contracts for cell and gene therapies in general “are promising, are moving forward, and this is...